Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing DCCR (diazoxide choline) extended-release tablets for Prader-Willi Syndrome (PWS), a rare genetic disorder affecting approximately 15,000-20,000 patients in the US. The company submitted its New Drug Application (NDA) to the FDA in 2024 and is awaiting regulatory approval, representing a binary catalyst for the stock. With zero revenue, strong cash position (16.08 current ratio), and negative operating cash flow of $100M annually, this is a pure-play regulatory approval bet on a potential orphan drug franchise.
Soleno operates a classic orphan drug development model targeting a rare disease with high unmet medical need. If approved, DCCR would address hyperphagia (insatiable hunger) in PWS patients, a condition with no FDA-approved pharmacological treatments. Pricing power in orphan diseases is typically strong due to small patient populations (15,000-20,000 addressable patients in US), lack of alternatives, and willingness of payers to cover life-altering therapies. Revenue model would be annual per-patient pricing likely in the $100,000-$300,000 range based on comparable orphan drugs, generating potential peak sales of $300M-$600M in the US alone if high penetration achieved. Currently burns approximately $100M annually on clinical development, regulatory activities, and pre-commercialization infrastructure.
FDA regulatory decision on DCCR NDA - binary approval/rejection catalyst representing primary near-term driver
Clinical data readouts or post-marketing study results demonstrating efficacy/safety in PWS population
Commercial launch execution metrics if approved - patient enrollment rates, prescriber adoption, reimbursement coverage decisions
Cash runway updates and financing activities - equity raises dilute shareholders but extend operational timeline
Competitive developments in PWS treatment landscape or alternative therapeutic approaches
Orphan drug designation maintenance and potential label expansion opportunities
Binary FDA approval risk - NDA rejection would eliminate near-term value proposition and require additional costly trials or program termination
Orphan drug market size constraints - addressable PWS population of 15,000-20,000 US patients limits peak revenue potential versus large indication drugs
Reimbursement uncertainty - payers may challenge pricing or impose restrictive coverage criteria despite orphan status, limiting commercial uptake
Single-asset dependency - entire company value tied to DCCR success with no diversified pipeline or revenue-generating products
Regulatory pathway evolution - FDA standards for rare disease approvals may tighten, requiring larger or longer-duration studies
Alternative PWS treatment approaches in development - gene therapies, other small molecules, or behavioral interventions could erode market share
Standard of care evolution - improvements in multidisciplinary PWS management (dietary, behavioral) may reduce perceived need for pharmacotherapy
Generic or biosimilar risk post-patent expiration - though orphan exclusivity provides 7-year market protection upon approval
Larger pharmaceutical companies could enter PWS space with greater resources if market validates commercial opportunity
Cash burn rate of $100M annually requires careful runway management - potential dilutive equity raises if approval delayed or commercial ramp slower than expected
Pre-revenue status means no organic cash generation to fund operations - entirely dependent on capital markets access
Negative ROE of -25.9% and ROA of -13.2% reflect ongoing losses, though typical for clinical-stage biotech
Manufacturing scale-up capital requirements post-approval could strain cash reserves if launch timing accelerates
low - Rare disease treatments for serious genetic disorders are medically necessary and non-discretionary. PWS patients require continuous management regardless of economic conditions. However, biotech sector valuations are cyclical and correlate with risk appetite, IPO markets, and broader healthcare spending trends. Economic downturns can pressure biotech stock multiples even when underlying business fundamentals are insulated.
Rising interest rates negatively impact Soleno through multiple channels: (1) Higher discount rates compress NPV of future cash flows, particularly punitive for pre-revenue companies with distant profitability; (2) Increases cost of capital for future financing needs, though company currently has strong cash position; (3) Risk-off sentiment in rate-hiking cycles reduces speculative capital flows to clinical-stage biotech; (4) Competition from risk-free rates makes high-risk biotech investments less attractive on relative basis. Rate cuts would provide valuation tailwind.
Minimal direct credit exposure given pre-revenue status and strong balance sheet (0.01 debt/equity ratio). Company is equity-financed with negligible debt obligations. However, tightening credit conditions indirectly impact ability to raise growth capital and can compress biotech sector multiples broadly. Post-approval, would need to establish commercial credit facilities for working capital, but this is not current concern.
growth/speculative - Attracts biotech-focused investors, event-driven hedge funds playing binary FDA catalysts, and rare disease specialists. High-risk/high-reward profile appeals to investors comfortable with clinical-stage volatility and regulatory uncertainty. Not suitable for income or value investors given zero revenue, negative cash flow, and absence of dividends. Requires conviction in PWS market opportunity and DCCR clinical profile. Typical holders include biotech-dedicated funds, crossover healthcare investors, and momentum traders around regulatory catalysts.
high - Clinical-stage biotech with single-asset focus exhibits extreme volatility around regulatory events, clinical data releases, and financing activities. Stock has declined 42.2% over six months and 18.7% over one year, reflecting sector-wide biotech weakness and binary risk premium. Beta likely exceeds 1.5 relative to broader market. Daily price swings of 10-30% common around FDA communications or competitive developments. Volatility will persist until revenue generation and commercial validation reduce uncertainty.
